949 related articles for article (PubMed ID: 10492501)
1. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
Evans ME; Feola DJ; Rapp RP
Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
[TBL] [Abstract][Full Text] [Related]
2. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
3. Rational use of intravenous polymyxin B and colistin: A review.
Zakuan ZD; Suresh K
Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
[TBL] [Abstract][Full Text] [Related]
4. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
5. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
Kassamali Z; Danziger L
Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
Doymaz MZ; Karaaslan E
Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
[No Abstract] [Full Text] [Related]
7. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
[TBL] [Abstract][Full Text] [Related]
8. Colistin, mechanisms and prevalence of resistance.
Bialvaei AZ; Samadi Kafil H
Curr Med Res Opin; 2015 Apr; 31(4):707-21. PubMed ID: 25697677
[TBL] [Abstract][Full Text] [Related]
9. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
[TBL] [Abstract][Full Text] [Related]
10. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
11. Polymyxin B versus colistin: an update.
Cai Y; Lee W; Kwa AL
Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
[TBL] [Abstract][Full Text] [Related]
12. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
Huang J; Tang YQ; Sun JY
Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
15. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
Kassamali Z; Jain R; Danziger LH
Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant Gram-negative infections: the use of colistin.
Michalopoulos AS; Karatza DC
Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
[TBL] [Abstract][Full Text] [Related]
17. Critical Role of Position 10 Residue in the Polymyxin Antimicrobial Activity.
Patil NA; Ma W; Jiang X; He X; Yu HH; Wickremasinghe H; Wang J; Thompson PE; Velkov T; Roberts KD; Li J
J Med Chem; 2023 Feb; 66(4):2865-2876. PubMed ID: 36745479
[TBL] [Abstract][Full Text] [Related]
18. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Vardakas KZ; Falagas ME
Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
[TBL] [Abstract][Full Text] [Related]
19. Clinical Use of Polymyxin B.
Rigatto MH; Falci DR; Zavascki AP
Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080
[TBL] [Abstract][Full Text] [Related]
20. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
Gales AC; Reis AO; Jones RN
J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]